[Validation of the Russian version of the modified Addenbrooke's cognitive examination for Alzheimer's disease diagnosis].

Aim: To evaluate the validity of the Russian version of the modified Addenbrooke's cognitive examination (ACE-m) for Alzheimer's disease (AD) diagnosis.

Material And Methods: ACE-m and MMSE, as a comparison scale, were administered to 78 patients including 49 patients with AD and 29 healthy people.

Results And Conclusion: ACE-m demonstrated the high validity in the diagnosis of dementia in AD.

[Cerebral amyloid angiopathy].

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of Β-amyloid protein in the media and adventitia of small arteries and capillaries. It may be an independent disease, but is often combined with Alzheimer's disease (AD). This review will discuss up-to-date understanding of the pathophysiology, clinical manifestations of CAA, its diagnosis with neuroimaging and biomarkers.

[Clinical, neuropsychological and neuroimaging features of patients with mixed dementia].

Objective. Mixed dementia (MD), characterized by a combination of Alzheimer's disease (AD) and cerebrovascular disease, is one of the most common and, at the same time, poorly diagnosed forms of dementia in the elderly. The aim of our study was to investigate features of AD with its combination with cerebrovascular disease on the basis of clinical, neuropsychological and neuroimaging data.

[Neuroprotective potential of akatinol-memantine in ischemic stroke].

NMDA-mediated excitotoxicity considered as a main cause of neuronal death after stroke. Memantine is a non-competitive NMDA-receptor antagonist. This article reviews the recent results of experimental studies on the efficacy of memantine as an add-on to improve the safety of thrombolytic therapy.

[Cerebral microbleeds in cerebrovascular and neurodegenerative diseases].

Cerebral microbleeds (CMBs) are a kind of the morphological changes of the brain associated with damage to small cerebral arteries detected on GRE MRI as small, round, well-defined, hypointense lesions, sized 3-10 mm, which indicate the deposition of hemosiderin. CMBs can be detected in cerebral microangiopathy of different origins (cerebral amyloid angiopathy, hypertensive arteriopathy, vasculitis, hereditary angiopathy) and may be a predictor of macrobleeds. This article discusses the clinical significance of CMBs in cerebrovascular, neurodegenerative diseases, cognitive disorders as well as the possibility of using antiplatelet agents and anticoagulants in patients with CMBs.